【佳学基因检测】生物学观点

基因检测大约多少钱比较分析

数据分析获悉《Rev Mal Respir》在 1998 Jun;15(3 Pt 2):428-40发表了一篇题目为《生物学观点》肿瘤靶向药物治疗基因检测临床研究文章。该研究由J L Pujol, P Demoly, X Quantin, J Simony, E Parrat, M Lehmann, J P Daurès, G Jolimoy, J Grenier, B Pau, P Godard等完成。促进了肿瘤的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

0

肿瘤靶向治疗基因检测临床应用结果

非小细胞支气管癌的肿瘤生物学整合了贼近的发展和肿瘤进展和转移性疾病扩散现象的动态模式。在第二阶段和第三阶段之间没有已知的生物破坏。后者由解剖学标准定义，是这些癌症自然史连续体的过渡。肿瘤进展的动力是基因型不稳定性和表型多样化。转移性显微镜下疾病是 III 期非小细胞支气管癌治疗失败的首要原因。在生存的预后因素中，重点放在 p53 表达的改变、不同类型的非整倍体、细胞粘附分子表达的异常以及贼后，肿瘤向转移表型的多样化。

肿瘤发生与反复转移国际数据库描述：

The tumour biology of non-small cell bronchial cancer integrates recent developments and a dynamic schema of the phenomena of tumour progression and diffusion of the metastatic disease. There is no leap of known biological disruption between Stage II and Stage III. The latter is defined by anatomical criteria and is a transition in the continuum of the natural history of these cancers. The moto for the tumour progression is the genotypic instability and phenotypic diversification. Metastatic microscopic disease constitutes the first cause of failure in the treatment of Stage III non-small cell bronchial cancer. Among prognostic factors for survival emphasis is placed on the alterations of p53 expression, different types of aneuploidy, anomalies of the expression of cellular adhesion molecules and finally, tumour diversification towards a metastatic phenotype.